This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Akishita, M. Articles by Horiuchi, M. Search for Related Content PubMed PubMed Citation Articles by Akishita, M. Articles by Horiuchi, M. Related Collections Remodeling

(Circulation. 2000;102:1684.)
© 2000 American Heart Association, Inc.

Basic Science Reports

Inhibitory Effect of Angiotensin II Type 2 Receptor on Coronary Arterial Remodeling After Aortic Banding in Mice

Masahiro Akishita, MD, PhD; Masaru Iwai, MD, PhD; Lan Wu, MD; Lunan Zhang, MD; Yasuyoshi Ouchi, MD, PhD; Victor J. Dzau, MD; Masatsugu Horiuchi, MD, PhD

From Cardiovascular Research, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (M.A., L.Z., V.J.D., M.H.); and Department of Geriatric Medicine, Kyorin University School of Medicine, Tokyo (M.A.), Department of Medical Biochemistry, Ehime University School of Medicine, Ehime (M.I., W.L., M.H.), and Department of Geriatric Medicine, Graduate School of Medicine, University of Tokyo, Tokyo (Y.O.), Japan.

Correspondence to Masatsugu Horiuchi, MD, PhD, Department of Medical Biochemistry, Ehime University School of Medicine, Shigenobu, Onsen-gun, Ehime 791-0295, Japan. E-mail horiuchi{at}m.ehime-u.ac.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—The renin-angiotensin system is thought to be critical for the development of cardiac hypertrophy, whereas the role of the angiotensin II type 2 (AT₂) receptor in the process is not defined. Using the AT₂ receptor–null (Agtr2-) mouse, we tested the hypothesis that the AT₂ receptor could exert an antigrowth effect in cardiac hypertrophy.

Methods and Results—Cardiac hypertrophy was induced by suprarenal abdominal aortic banding in 10- to 12-week-old Agtr2- and wild-type (Agtr2+) mice for 6 or 12 weeks. Carotid arterial pressure was not different between the strains, although aortic banding increased arterial pressure by 40 mm Hg. Aortic banding increased the heart-weight/body-weight ratio and the cross-sectional area of cardiomyocytes by 15%, resulting in comparable cardiomyocyte hypertrophy in the 2 strains. In contrast, coronary arterial thickening and perivascular fibrosis, determined by the media/lumen-area ratio and the collagen/vessel-area ratio, respectively, were 50% greater in Agtr2- than in Agtr2+ mice after banding, whereas these parameters were similar in sham-operated mice. Radioligand binding studies using the whole heart and immunohistochemistry showed that AT₂ receptor expression was limited and localized in the coronary artery and perivascular region.

Conclusions—These results suggest that the AT₂ receptor mediates an inhibitory effect on coronary arterial remodeling, such as medial hypertrophy and perivascular fibrosis in response to pressure overload, and an activation of the renin-angiotensin system.

Key Words: angiotensin • receptors • muscle, smooth • myocytes • collagen

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Cardiac hypertrophy is an adaptive response to hemodynamic or nonhemodynamic stimuli, such as hypertension and myocardial infarction, and is a major risk factor for heart failure. ACE inhibitors prevent progression and induce regression of cardiac hypertrophy in hypertensive patients^{1 2} as well as in experimental animal models.^{3 4} Components of the renin-angiotensin-aldosterone system (RAAS), including angiotensinogen, renin, and ACE, are upregulated in the hypertrophied heart.⁵ These findings suggest that the RAAS plays a critical role in the development of cardiac hypertrophy.

Most of the known actions of angiotensin II, an effector peptide in the renin-angiotensin system, are mediated by the well-characterized angiotensin II type 1 (AT₁) receptor.⁶ The functions of the recently cloned type 2 (AT₂) receptor,^{7 8} however, are still unclear. The recent increase in the clinical application of AT₁ receptor blockers versus ACE inhibitors for the treatment of hypertension and heart failure has raised a question concerning the role of the AT₂ receptor in cardiac hypertrophy. Several studies have shown that AT₂ receptor expression is upregulated in the hypertrophied^{9 10} or failing¹¹ heart, although this upregulation may be species-dependent. In vitro studies have demonstrated that AT₂ receptor stimulation inhibits the growth of various cell types, including vascular smooth muscle cells,¹² cardiomyocytes,^{13 14} and cardiac fibroblasts,¹⁴ by counteracting AT₁ receptor signaling. These findings have led us to hypothesize that the AT₂ receptor could exert antigrowth effects on the development of cardiac hypertrophy.

Thus, to test this hypothesis, we developed cardiac hypertrophy by abdominal aortic banding in the AT₂ receptor–deficient (Agtr2-) mouse.¹⁵ By comparing it with the littermate wild-type (Agtr2+) mouse, we demonstrated that coronary arterial thickening and coronary perivascular fibrosis were exaggerated in the Agtr2- mouse, whereas hypertrophy of cardiomyocytes was similar in the 2 strains.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animals
Pairs of adult male Agtr2- and Agtr2+ littermates were used in this study. Because the AT₂ receptor gene is located on the X chromosome, heterozygous females were mated with Agtr2+ males to obtain hemizygous and Agtr2+ males. Animal genotyping was performed as previously described.¹⁵ These mice, back-crossed for 6 generations into the FVB/N background, had 98% FVB/N and 2% 129/SV background on average. All mice used in this study were 10 to 12 weeks of age and weighed 25 to 30 g. The mice were housed in a room where lighting was controlled (12 hours on, 12 hours off) and room temperature was kept at 22°C. They were given a standard diet and water ad libitum. All experimental procedures were approved and carried out in accordance with the guidelines of the Harvard Medical Area Standing Committee on Animals.

Surgical Procedures
All surgical procedures were performed under anesthesia with ketamine (70 mg/kg) and xylazine (4 mg/kg) administered by IP injection. Abdominal aortic banding was performed as described previously,¹⁶ with some modification. Briefly, the abdominal aorta was constricted at the suprarenal level with 7-0 nylon sutures together with a blunted 30-gauge needle, which was pulled out thereafter. Sham operation was performed by isolation of the aorta without ligation. After the experimental period, the hemodynamic effects of aortic constriction were monitored. A polyethylene catheter (PE10; Becton Dickinson) was inserted into the left common carotid artery, tunneled under the skin, and exteriorized at the back of the neck. In some mice, another catheter (PE10) was inserted into the left femoral artery to monitor the pressure gradient between the carotid and femoral arteries. The mice were allowed to recover overnight, then, with the mice in a conscious and unrestrained condition, arterial pressure and heart rate were recorded over 60 minutes through the catheter connected to a Statham pressure transducer. The mice were killed by an overdose of anesthesia and perfused with PBS via the arterial catheter. Subsequently, the heart was perfusion-fixed at 100 mm Hg with 10% neutral buffered formalin. The hearts were excised, weighed, and postfixed in 10% neutral buffered formalin for histological analysis. For receptor binding assay and immunohistochemistry, the hearts were dissected after perfusion with PBS, immediately frozen in liquid nitrogen, and stored at -80°C.

Morphometric Analysis
Fixed hearts were dehydrated and embedded in paraffin. The middle segment of the heart was cut into 5 subserial cross sections 5 µm thick at intervals of 0.3 mm. The sections were stained with hematoxylin and eosin for examination of overall morphology or with van Gieson’s stain for examination of coronary arterial thickness and collagen.¹⁶ The regions in the left and right ventricular free wall were used for analysis. Myocyte cross-sectional area was measured in sections stained with hematoxylin and eosin, and suitable cross sections were defined as having nearly circular capillary profiles and nuclei.¹⁶ To evaluate coronary arterial thickening and perivascular fibrosis, circular coronary arteries with a long-axis–to–short-axis ratio <1.3 were chosen as suitable cross sections. Wall-area–to–lumen-area ratio, an index of arterial thickening, was defined as the ratio of cross-sectional medial area to luminal area. Perivascular fibrosis was assessed by calculating the ratio of the area of collagen-stained fibrosis to total vessel area, which was defined as medial area plus luminal area. Each field was scanned together with a microscale by a CCD camera connected to a Macintosh computer and analyzed with image-analyzing software (NIH Image Ver. 1.61) by an observer blinded to the animal genotype and treatment. The average of >20 regions for myocytes and >10 regions for coronary arteries was taken as the value for each animal.

Radioligand Binding Assay
Binding assays were performed with crude membranes isolated from the hearts (n=3 for each group) as previously described.^{7 17} Membrane fractions (100 µg protein) were incubated for 2 hours at room temperature in 100 µL of 20 mmol/L Tris-HCl (pH 7.4) containing 0.25% BSA and 0.2 nmol/L ¹²⁵I-labeled [Sar¹,Ile⁸]angiotensin II (NEN Life Science Products) in the absence (for the total count) or presence of 1 µmol/L losartan (Merck & Co, Inc) or 1 µmol/L PD123319 (Research Biochemicals International). Bound and free ligands were separated with GF/C filters (Whatman). AT₁ receptor binding was calculated as the difference between the total count and the count from samples incubated with losartan. AT₂ receptor binding was determined by subtracting the count of samples incubated with PD123319 from the total count. The net radioactivity count was converted to molar values by use of specific activity of the ligand.

Immunohistochemistry
Frozen sections (5 µm thick) were immunohistochemically stained by the streptavidin-biotin-peroxidase method as described previously.¹⁸ Briefly, endogenous peroxidase and the nonspecific binding of the antibody were blocked with 0.3% hydrogen peroxide in methanol and 2% goat serum in PBS, respectively. The antibody to the AT₂ receptor (gift from Dr Robert M. Carey, University of Virginia Health Sciences Center; diluted 1:500) or normal rabbit serum diluted in 1% BSA in PBS was applied to the sections and incubated for 16 to 24 hours at 4°C. Subsequently, biotinylated secondary antibody and then streptavidin-peroxidase conjugate were applied. Positive staining was visualized with diaminobenzidine and counterstained with hematoxylin.

Data Analysis
Values are expressed as mean±SEM in the text, table, and figures. Data were analyzed by 1-factor ANOVA. If a statistically significant effect was found, the Newman-Keuls test was performed to isolate the difference between the groups. A value of P<0.05 was considered to be significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Hemodynamic Effects of Aortic Banding
Suprarenal aortic banding for 6 weeks produced a systolic pressure gradient of nearly 40 mm Hg between the carotid and femoral arteries (Agtr2+, 38±5 mm Hg; Agtr2-, 39±3 mm Hg, n=6). Carotid mean arterial pressure (MAP), heart rate, and body weight after aortic banding (Banding) or sham operation (Sham) for 6 or 12 weeks are shown in the Table. MAP in the Sham groups was comparable in Agtr2+ and Agtr2- mice. Aortic banding for 6 or 12 weeks increased MAP by 35 mm Hg in the 2 strains compared with that in the corresponding Sham groups. Accordingly, no significant difference was found in MAP after aortic banding between Agtr2+ and Agtr2- mice. Heart rate and body weight were similar in the groups.

View this table: [in this window] [in a new window]   Table 1. Body Weight, MAP, and Heart Rate in Agtr2+ and Agtr2- Mice After Aortic Banding (Banding) or Sham Operation (Sham)

Cardiomyocyte Hypertrophy
The degree of cardiomyocyte hypertrophy was evaluated by calculating the ratio of heart weight to body weight (HW/BW ratio) and by measurement of the cross-sectional area of cardiomyocytes. As shown in Figure 1A, HW/BW ratio was not different between sham-operated Agtr2+ and Agtr2- mice at 6 and 12 weeks. Aortic banding increased HW/BW ratio by 15% in the 2 strains, resulting in similar HW/BW ratio in Agtr2+ and Agtr2- mice at 6 and 12 weeks after banding. Consistent with this result, there was no significant difference in the cross-sectional area of cardiomyocytes in the left ventricle between Agtr2+ and Agtr2- mice in the Sham and Banding groups at 6 and 12 weeks (Figure 1B). The cross-sectional area of cardiomyocytes in the right ventricle was not increased by aortic banding or did not differ between Agtr2+ and Agtr2- mice (data not shown).

View larger version (39K): [in this window] [in a new window]   Figure 1. Ratio of heart weight to body weight (A) and cross-sectional area of cardiomyocytes in left ventricle (B) were examined in Agtr2+ and Agtr2- mice after sham operation (Sham) or aortic banding (Banding) for 6 or 12 weeks. *P<0.05 vs Sham. Each bar indicates mean±SEM of 6 to 8 animals.

Coronary Arterial Thickening and Perivascular Fibrosis
Coronary arterial thickening and perivascular fibrosis were observed in the heart after aortic banding, but interstitial fibrosis was not. As shown in Figure 2A, these histopathological changes were exaggerated in the Agtr2- mouse. To quantitatively analyze the histology, we measured the medial area of the coronary artery and the area of fibrosis, then calculated each index in the large (100 diameter <200 µm) and small (50 diameter <100 µm) coronary arteries separately, because the index-diameter relationship was different between large and small arteries.

View larger version (52K): [in this window] [in a new window]   Figure 2. Representative cross sections of coronary artery (A) and bar graphs showing coronary arterial thickening (B) and perivascular fibrosis (C) in left ventricle in Agtr2+ and Agtr2- mice after sham operation (Sham) or aortic banding (Banding). A, Coronary artery and cardiomyocytes are stained yellow and collagen is stained red with van Gieson’s stain. Thickened coronary artery and augmented perivascular fibrosis are apparent in Agtr2- mouse after aortic banding for 6 weeks. Magnification x100. B and C, *P<0.05 vs Sham; §P<0.05 vs Agtr2+. Each bar indicates mean±SEM of 6 to 8 animals.

As shown in Figure 2B, wall-area–to–lumen-area ratio, an index of coronary arterial thickening, in the left ventricle was greater in Agtr2- than in Agtr2+ mice at 6 and 12 weeks after banding, whereas it was similar in sham-operated Agtr2+ and Agtr2- mice.

The ratio of collagen area to total vessel area, an index of perivascular fibrosis, in the left ventricle was also greater in Agtr2- than in Agtr2+ mice at 6 and 12 weeks after banding, whereas they were similar in sham-operated Agtr2+ and Agtr2- mice (Figure 2C).

Morphological changes of coronary arteries in the right ventricle were also examined. Because the number of large coronary arteries was limited in the right ventricle, only the small coronary arteries were analyzed at 12 weeks. Sham-operated Agtr2+ and Agtr2- mice showed comparable wall-area–to–lumen-area ratio (Agtr2+, 0.200±0.016; Agtr2-, 0.206±0.011; n=8) and collagen-area–to–total-vessel-area ratio (Agtr2+, 0.084±0.010; Agtr2-, 0.094±0.008; n=8). After banding, however, wall-area–to–lumen-area ratio was greater in Agtr2- than in Agtr2+ mice, although the strain difference was smaller than that observed in the left ventricle (Agtr2+, 0.210±0.008; Agtr2-, 0.288±0.018; P<0.05, n=7). Similarly, the ratio of collagen area to total vessel area was greater in Agtr2- than in Agtr2+ mice (Agtr2+, 0.117±0.010; Agtr2-, 0.220±0.032; P<0.05, n=7).

AT₂ Receptor Expression in the Heart
Receptor binding activity was examined by use of the membrane fraction of the whole heart. As shown in Figure 3A, most of the binding consisted of AT₁-specific binding even in the Agtr2+ mouse after aortic banding. AT₂-specific binding was not significantly greater in the Agtr2+ mouse in any treatment group than in the Agtr2- mouse. These results suggest that the AT₂ receptor was not upregulated, at least in the heart overall, in this mouse model of cardiac hypertrophy. Furthermore, AT₁ receptor binding was not different between the strains or the treatments.

View larger version (48K): [in this window] [in a new window]   Figure 3. A, Ligand binding study of AT1 and AT2 receptors using membrane fraction prepared from whole hearts in Agtr2+ and Agtr2- mice after sham operation (Sham) or aortic banding (Banding). Each bar indicates mean±SEM of 3 animals. One representative result of 2 independent experiments is shown. B through D, Subserial cross sections of coronary artery prepared from Agtr2+ mice 6 weeks after aortic banding were immunohistochemically stained with antibody to AT2 receptor (B) or normal rabbit serum (D) or stained with van Gieson’s stain (C). Sections B and D were counterstained with hematoxylin. Magnification x400.

To localize the AT₂ receptor expression in the hypertrophied heart, we performed immunohistochemical studies. As shown in Figure 3, B through D, positive staining for the AT₂ receptor was observed predominantly in the coronary artery and perivascular region of Agtr2+ mice.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Histological changes in the hypertrophied heart include cardiomyocyte hypertrophy, coronary arterial thickening, and perivascular fibrosis.¹⁹ In the present study, suprarenal aortic banding induced these morphological changes in mice. Of interest, coronary arterial thickening and perivascular fibrosis were exaggerated in the Agtr2- mouse compared with the Agtr2+ mouse, whereas cardiomyocyte hypertrophy developed similarly in the 2 strains. Cardiac morphology and arterial pressure did not differ between Agtr2+ and Agtr2- mice without banding. In addition, arterial pressure after aortic banding was comparable in Agtr2+ and Agtr2- mice. Although another reported AT₂ receptor–null mouse strain²⁰ and our Agtr2- mouse strain have shown increased arterial pressure at baseline²⁰ or in response to angiotensin II,^{15 20} the results of the present study indicate that different morphological changes were induced in the 2 strains at the same level of hypertension.

Suprarenal aortic banding creates renal ischemia as well as arterial hypertension, leading to RAAS activation and subsequent coronary remodeling of the pressure-overloaded left ventricle and the nonoverloaded right ventricle.^{19 21} Thus, to study whether an activation of the RAAS would play an important role in the structural abnormalities in Agtr2- mice, we further examined coronary arterial thickening and perivascular fibrosis in the right ventricle. Importantly, Agtr2- mice showed exaggerated coronary remodeling of the right ventricle as well. This suggests that humoral factors, such as circulating angiotensin II, exerted trophic effects on the right ventricular coronary artery. The reason why the strain difference was smaller in the right ventricle than in the left ventricle may be attributable to the presence or absence of the pressure overload–induced RAAS activation in the myocardium.

In vitro cell culture studies suggest that the AT₂ receptor exerts growth-inhibitory effects in AT₂ receptor cDNA–transfected vascular smooth muscle cells,^{12 22} coronary endothelial cells,²³ neonatal cardiomyocytes,^{13 14} and cardiac fibroblasts.¹⁴ Using in vivo transfer of the AT₂ receptor gene into the balloon-injured rat carotid artery,¹² we have also shown that the AT₂ receptor can inhibit vascular smooth muscle cell growth in vivo. On the basis of these results, we investigated whether the AT₂ receptor, which is expressed and/or upregulated in the hypertrophied heart, could mediate the antigrowth effect in cardiac hypertrophy.

In the present study, coronary arterial thickening and perivascular collagen deposition (fibrosis) were augmented in Agtr2- mice, whereas cardiomyocyte hypertrophy was not. Localization and/or the expression level of the AT₂ receptor may account for these apparently conflicting results in terms of the antigrowth action of the AT₂ receptor. Indeed, ligand-binding studies revealed that AT₂ receptor–binding activity was negligible even in the Agtr2+ mouse heart. Because the membrane fraction of the whole heart consisted predominantly of cardiomyocytes, this result suggests that the expression of the AT₂ receptor in cardiomyocytes, with or without hypertrophy, was scanty in our experimental conditions, although some reports have shown baseline^{24 25} or hypertrophy-induced^{9 10} expression of the AT₂ receptor in cardiomyocytes. Localized and limited expression of the AT₂ receptor in other cell types might not be detected by the binding assay. If so, which cell type is responsible for the possible expression of the AT₂ receptor and its effect observed in this study? Our immunohistochemical studies showed that positive staining for the AT₂ receptor was localized in the coronary artery and perivascular region. The results suggest that fibroblasts, smooth muscle cells, and endothelial cells contain the AT₂ receptor, although the expression level and cellular localization are still unclear. It has been reported that fibroblasts are the major cell type expressing the AT₂ receptor in the diseased human heart.^{11 24} In addition, Tsutsumi et al¹¹ examined AT₂ receptor signaling using the fibroblast compartment of the failing heart and confirmed the finding of the previous in vitro studies^{26 27} that the AT₂ receptor exerted an inhibitory effect on p44/42 mitogen-activated protein kinase by counteracting the AT₁ receptor. Coronary endothelial cells are also reported to contain the AT₂ receptor.^{23 25} The AT₂ receptor in fibroblasts and smooth muscle cells could inhibit fibrosis and medial thickening, respectively, by directly regulating cell growth. Alternatively, the AT₂ receptor may modulate the production of vasoactive substances, such as nitric oxide²⁸ and bradykinin.²⁹ Thus, the AT₂ receptors in endothelial cells, fibroblasts, and smooth muscle cells might influence each other by regulating growth and/or vascular tone in a paracrine fashion. Taken together, it can be hypothesized that the AT₂ receptor expressed in perivascular fibroblasts, coronary endothelial cells, and/or smooth muscle cells exerted antigrowth effects directly or indirectly by interaction of the cell types in the process of cardiac hypertrophy. To address the exact localization and the level of AT₂ receptor expression in the hypertrophied heart, which is still controversial,^{9 10 11 24} more detailed and fine time-course studies that use in situ hybridization, binding autoradiography, or immunohistochemistry are needed in the future. Because our binding assay and immunohistochemistry are too preliminary to exclude the possible AT₂ receptor expression in cardiomyocytes, the role of the AT₂ receptor in cardiomyocyte hypertrophy remains unclear. Other cardiac hypertrophy models or transgenic mice overexpressing the AT₂ receptor specifically in cardiomyocytes³⁰ may be useful to address this issue.

Coronary arterial thickening as a result of vascular smooth muscle cell hypertrophy or hyperplasia may lead to coronary artery narrowing and decreased coronary reserve.³¹ Indeed, medial thickening of the coronary arterioles >50 µm in diameter, which we defined as the small arteries, is reported to contribute to the increase in peripheral vascular resistance.³² Similarly, perivascular fibrosis alters vasomotor reactivity of intramural coronary arteries,³¹ and cardiac fibrosis may lead to decreased compliance and increased myocardial stiffness.¹⁹ Therefore, the finding of the present study concerning coronary arterial thickening and perivascular fibrosis suggests the pathophysiological and clinical importance of the AT₂ receptor in cardiac hypertrophy. Because activation of the RAAS is critical for these structural changes, blockade of the AT₁ receptor may not only abrogate AT₁ receptor signaling but also stimulate the AT₂ receptor, leading to inhibition of coronary arterial remodeling, such as medial hypertrophy and perivascular fibrosis.

In summary, coronary arterial thickening and perivascular fibrosis, but not cardiomyocyte hypertrophy, in response to pressure overload and RAAS activation were exaggerated in AT₂ receptor–null mice compared with wild-type mice. These results provide a new implication of the AT₂ receptor in cardiac hypertrophy.

	Acknowledgments

 
This work was supported by NIH grants HL-46631, HL-35252, HL-35610, HL-48638, HL-07708, and HL-58616; a grant from Longwood Foundation for Translational Research; and grants from the Japan Cardiovascular Research Foundation, Suzuken Memorial Foundation, Takeda Scientific Foundation, and NOVARTIS Foundation for the Promotion of Science. Victor J. Dzau is a recipient of NIH Merit Award HL-35610.

Received March 9, 2000; revision received May 3, 2000; accepted May 8, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol. 1984;53:1044–1049.[Medline] [Order article via Infotrieve]
   
2. Garavaglia GE, Messerli FH, Nunez BD, et al. Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension. Am J Cardiol. 1988;62:912–916.[Medline] [Order article via Infotrieve]
   
3. Pfeffer JM, Pfeffer MA, Mirsky I, et al. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A. 1982;79:3310–3314.[Abstract/Free Full Text]
   
4. Baker KM, Chernin MI, Wixson SK, et al. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol. 1990;259:H324–H332.[Abstract/Free Full Text]
   
5. Yamazaki T, Yazaki Y. Is there major involvement of the renin-angiotensin system in cardiac hypertrophy? Circ Res. 1997;81:639–642.
   
6. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153:937–942.[Abstract]
   
7. Mukoyama M, Nakajima M, Horiuchi M, et al. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem. 1993;268:24539–24542.[Abstract/Free Full Text]
   
8. Kambayashi Y, Bardhan S, Takahashi K, et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem. 1993;268:24543–24546.[Abstract/Free Full Text]
   
9. Lopez JJ, Lorell BH, Ingelfinger JR, et al. Distribution and function of cardiac angiotensin AT₁- and AT₂-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994;267:H844–H852.[Abstract/Free Full Text]
   
10. Suzuki J, Matsubara H, Urakami M, et al. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 1993;73:439–447.[Abstract/Free Full Text]
    
11. Tsutsumi Y, Matsubara H, Ohkubo N, et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res. 1998;83:1035–1046.[Abstract/Free Full Text]
    
12. Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II type 2 (AT₂) receptor antagonizes the growth effects of the AT₁ receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92:10663–10667.[Abstract/Free Full Text]
    
13. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II–induced cardiomyocyte hypertrophy. Hypertension. 1996;28:635–640.[Abstract/Free Full Text]
    
14. van Kesteren CA, van Heugten HA, Lamers JM, et al. Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. J Mol Cell Cardiol. 1997;29:2147–2157.[Medline] [Order article via Infotrieve]
    
15. Hein L, Barsh GS, Pratt RE, et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 1995;377:744–747.[Medline] [Order article via Infotrieve]
    
16. Harada K, Komuro I, Shiojima I, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation. 1998;97:1952–1959.[Abstract/Free Full Text]
    
17. Akishita M, Ito M, Lehtonen JY, et al. Expression of the AT₂ receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. J Clin Invest. 1999;103:63–71.[Medline] [Order article via Infotrieve]
    
18. Akishita M, Horiuchi M, Yamada H, et al. Inflammation influences vascular remodeling through AT₂ receptor expression and signaling. Physiol Genomics. 2000;2:13–20.[Abstract/Free Full Text]
    
19. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849–1865.[Abstract/Free Full Text]
    
20. Ichiki T, Labosky PA, Shiota C, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995;377:748–750.[Medline] [Order article via Infotrieve]
    
21. Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355–1364.[Abstract/Free Full Text]
    
22. Yamada T, Akishita M, Pollman MJ, et al. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. Life Sci. 1998;63:PL289–PL295.[Medline] [Order article via Infotrieve]
    
23. Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT₂-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651–657.
    
24. Wharton J, Morgan K, Rutherford RA, et al. Differential distribution of angiotensin AT₂ receptors in the normal and failing human heart. J Pharmacol Exp Ther. 1998;284:323–336.[Abstract/Free Full Text]
    
25. Wang ZQ, Moore AF, Ozono R, et al. Immunolocalization of subtype 2 angiotensin II (AT₂) receptor protein in rat heart. Hypertension. 1998;32:78–83.[Abstract/Free Full Text]
    
26. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A. 1996;93:156–160.[Abstract/Free Full Text]
    
27. Huang XC, Richards EM, Sumners C. Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2 receptors. J Biol Chem. 1996;271:15635–15641.[Abstract/Free Full Text]
    
28. Siragy HM, Carey RM. The subtype 2 (AT₂) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;100:264–269.[Medline] [Order article via Infotrieve]
    
29. Siragy HM, Inagami T, Ichiki T, et al. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT₂) angiotensin receptor. Proc Natl Acad Sci U S A. 1999;96:6506–6510.[Abstract/Free Full Text]
    
30. Masaki H, Kurihara T, Yamaki A, et al. Cardiac-specific overexpression of angiotensin II AT₂ receptor causes attenuated response to AT₁ receptor-mediated pressor and chronotropic effects. J Clin Invest. 1998;101:527–535.[Medline] [Order article via Infotrieve]
    
31. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res. 1991;69:107–115.[Abstract/Free Full Text]
    
32. Vitullo JC, Penn MS, Rakusan K, et al. Effects of hypertension and aging on coronary arteriolar density. Hypertension. 1993;21:406–414.[Abstract/Free Full Text]
    

This article has been cited by other articles:

				X. Yan, A. J. T. Schuldt, R. L. Price, I. Amende, F.-F. Liu, K. Okoshi, K. K. L. Ho, A. J. Pope, T. K. Borg, B. H. Lorell, et al. Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1274 - H1281. [Abstract] [Full Text] [PDF]

				M. R. Bergman, J. R. Teerlink, R. Mahimkar, L. Li, B.-Q. Zhu, A. Nguyen, S. Dahi, J. S. Karliner, and D. H. Lovett Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1847 - H1860. [Abstract] [Full Text] [PDF]

				H. Okada, T. Inoue, T. Kikuta, Y. Watanabe, Y. Kanno, S. Ban, T. Sugaya, M. Horiuchi, and H. Suzuki A Possible Anti-Inflammatory Role of Angiotensin II Type 2 Receptor in Immune-Mediated Glomerulonephritis during Type 1 Receptor Blockade Am. J. Pathol., November 1, 2006; 169(5): 1577 - 1589. [Abstract] [Full Text] [PDF]

				A. Oshita, M. Iwai, R. Chen, A. Ide, M. Okumura, S. Fukunaga, T. Yoshii, M. Mogi, J. Higaki, and M. Horiuchi Attenuation of Inflammatory Vascular Remodeling by Angiotensin II Type 1 Receptor-Associated Protein Hypertension, October 1, 2006; 48(4): 671 - 676. [Abstract] [Full Text] [PDF]

				C. Warnecke, P. Mugrauer, D. Surder, J. Erdmann, C. Schubert, and V. Regitz-Zagrosek Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1729 - R1735. [Abstract] [Full Text] [PDF]

				A. D'Amore, M. J. Black, and W. G. Thomas The Angiotensin II Type 2 Receptor Causes Constitutive Growth of Cardiomyocytes and Does Not Antagonize Angiotensin II Type 1 Receptor-Mediated Hypertrophy Hypertension, December 1, 2005; 46(6): 1347 - 1354. [Abstract] [Full Text] [PDF]

				V. L. Sales, G. K. Sukhova, M. A. Lopez-Ilasaca, P. Libby, V. J. Dzau, and R. E. Pratt Angiotensin Type 2 Receptor Is Expressed in Murine Atherosclerotic Lesions and Modulates Lesion Evolution Circulation, November 22, 2005; 112(21): 3328 - 3336. [Abstract] [Full Text] [PDF]

				A. Hara, K.-i. Yuhki, T. Fujino, T. Yamada, K. Takayama, S. Kuriyama, O. Takahata, H. Karibe, Y. Okada, C.-Y. Xiao, et al. Augmented Cardiac Hypertrophy in Response to Pressure Overload in Mice Lacking the Prostaglandin I2 Receptor Circulation, July 5, 2005; 112(1): 84 - 92. [Abstract] [Full Text] [PDF]

				B. L. Falcon, S. J. Veerasingham, C. Sumners, and M. K. Raizada Angiotensin II Type 2 Receptor-Mediated Gene Expression Profiling in Human Coronary Artery Endothelial Cells Hypertension, April 1, 2005; 45(4): 692 - 697. [Abstract] [Full Text] [PDF]

				D. Perlegas, H. Xie, S. Sinha, A. V. Somlyo, and G. K. Owens ANG II type 2 receptor regulates smooth muscle growth and force generation in late fetal mouse development Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H96 - H102. [Abstract] [Full Text] [PDF]

				B. L. Falcon, J. M. Stewart, E. Bourassa, M. J. Katovich, G. Walter, R. C. Speth, C. Sumners, and M. K. Raizada Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension Physiol Genomics, November 17, 2004; 19(3): 255 - 261. [Abstract] [Full Text] [PDF]

				B. L. Metcalfe, M. J. Huentelman, L. D. Parilak, D. G. Taylor, M. J. Katovich, H. J. Knot, C. Sumners, and M. K. Raizada Prevention of Cardiac Hypertrophy by Angiotensin II Type-2 Receptor Gene Transfer Hypertension, June 1, 2004; 43(6): 1233 - 1238. [Abstract] [Full Text] [PDF]

				O. Johren, A. Dendorfer, and P. Dominiak Cardiovascular and renal function of angiotensin II type-2 receptors Cardiovasc Res, June 1, 2004; 62(3): 460 - 467. [Abstract] [Full Text] [PDF]

				G. W. Booz Cardiac Angiotensin AT2 Receptor: What Exactly Does It Do? Hypertension, June 1, 2004; 43(6): 1162 - 1163. [Full Text] [PDF]

				W. W. Batenburg, I. M. Garrelds, C. C. Bernasconi, L. Juillerat-Jeanneret, J. P. van Kats, P. R. Saxena, and A.H. J. Danser Angiotensin II Type 2 Receptor-Mediated Vasodilation in Human Coronary Microarteries Circulation, May 18, 2004; 109(19): 2296 - 2301. [Abstract] [Full Text] [PDF]

				B. I. Levy Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin-Angiotensin System Circulation, January 6, 2004; 109(1): 8 - 13. [Full Text] [PDF]

				M. Brede, W. Roell, O. Ritter, F. Wiesmann, R. Jahns, A. Haase, B. K. Fleischmann, and L. Hein Cardiac Hypertrophy Is Associated With Decreased eNOS Expression in Angiotensin AT2 Receptor-Deficient Mice Hypertension, December 1, 2003; 42(6): 1177 - 1182. [Abstract] [Full Text] [PDF]

				Z. Lako-Futo, I. Szokodi, B. Sarman, G. Foldes, H. Tokola, M. Ilves, H. Leskinen, O. Vuolteenaho, R. Skoumal, R. deChatel, et al. Evidence for a Functional Role of Angiotensin II Type 2 Receptor in the Cardiac Hypertrophic Process In Vivo in the Rat Heart Circulation, November 11, 2003; 108(19): 2414 - 2422. [Abstract] [Full Text] [PDF]

				X. Yan, R. L. Price, M. Nakayama, K. Ito, A. J. T. Schuldt, W. J. Manning, A. Sanbe, T. K. Borg, J. Robbins, and B. H. Lorell Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2179 - H2187. [Abstract] [Full Text] [PDF]

				L. Lu, T. Yao, Y.-Z. Zhu, G.-Y. Huang, Y.-X. Cao, and Y.-C. Zhu Chronic all-trans retinoic acid treatment prevents medial thickening of intramyocardial and intrarenal arteries in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1370 - H1377. [Abstract] [Full Text] [PDF]

				Y. Adachi, Y. Saito, I. Kishimoto, M. Harada, K. Kuwahara, N. Takahashi, R. Kawakami, M. Nakanishi, Y. Nakagawa, K. Tanimoto, et al. Angiotensin II Type 2 Receptor Deficiency Exacerbates Heart Failure and Reduces Survival After Acute Myocardial Infarction in Mice Circulation, May 20, 2003; 107(19): 2406 - 2408. [Abstract] [Full Text] [PDF]

				Y. Oishi, R. Ozono, Y. Yano, Y. Teranishi, M. Akishita, M. Horiuchi, T. Oshima, and M. Kambe Cardioprotective Role of AT2 Receptor in Postinfarction Left Ventricular Remodeling Hypertension, March 1, 2003; 41(3): 814 - 818. [Abstract] [Full Text] [PDF]

				Z. Li, M. Iwai, L. Wu, T. Shiuchi, T. Jinno, T.-X. Cui, and M. Horiuchi Role of AT2 receptor in the brain in regulation of blood pressure and water intake Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H116 - H121. [Abstract] [Full Text] [PDF]

				S. Kurisu, R. Ozono, T. Oshima, M. Kambe, T. Ishida, H. Sugino, H. Matsuura, K. Chayama, Y. Teranishi, O. Iba, et al. Cardiac Angiotensin II Type 2 Receptor Activates the Kinin/NO System and Inhibits Fibrosis Hypertension, January 1, 2003; 41(1): 99 - 107. [Abstract] [Full Text] [PDF]

R. E. Widdop, K. Matrougui, B. I. Levy, and D. Henrion AT2 Receptor-Mediated Relaxation Is Preserved After Long-Term AT1 Receptor Blockade Hypertension, October 1, 2002; 40(4): 516 - 520. [Abstract] [Full Text] [PDF]